Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Solid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Solid Neoplasm

Cancer Family

Solid Neoplasm

CI-CAN-00000052Explore in graph →

Non-malignant1,822 active trials28 evidence items

NCIt: C9292

Overview
Statistics
Survival
Genomics
Variants & evidence28
Drugs19
Trials6088
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (18)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–18 of 18 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838007 · validated civic_curation pubmed
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
· N Engl J Med · 2018 · PMID 29466156 · validated civic_curation pubmed
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
· J Clin Oncol · 2024 · PMID 37870536 · validated civic_curation pubmed
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
· Nat Med · 2023 · PMID 37059834 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697 · validated civic_curation pubmed
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
· Ann Oncol · 2019 · PMID 30624546 · validated civic_curation pubmed
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
· Lancet Oncol · 2020 · PMID 32105622 · validated

Showing 1–18 of 18 publications

civic_curation

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).

· Clin Cancer Res · 2020 · PMID 31924734 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

· Science · 2018 · PMID 30309915 · validated civic_curation pubmed

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.

· Clin Cancer Res · 2021 · PMID 33637626 · validated civic_curation pubmed

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration.

· Ann Oncol · 2024 · PMID 39293516 · validated civic_curation pubmed

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

· J Immunother Cancer · 2021 · PMID 33653800 · validated civic_curation pubmed

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

· Invest New Drugs · 2017 · PMID 28281183 · validated civic_curation pubmed

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.

· Cancer Res Commun · 2024 · PMID 38126764 · validated civic_curation pubmed

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

· Nature · 2017 · PMID 28783719 · validated civic_curation pubmed

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

· Br J Cancer · 2017 · PMID 28972961 · validated civic_curation pubmed